Direct Express is a well-established company based to the north of London – at Welham Green, Hertfordshire – which is close to the M25, M4, M3, M1 and A1(M).

Clinical research is becoming more patient-centric, but there’s still more that needs to be done to make clinical trials available to everyone. This could include wider participation. Pharmaceutical ...

Syneos Health Communications and Precision AQ led the agency list, while Novartis, Roche and Takeda shared the top client spot Over the course of 15 years, the PM Society Digital Awards have become a ...

Delivering on your brand or portfolio strategy can come with some sizeable questions that need to be tackled in order to progress. And not just progress but place you in the best position to achieve ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Pfizer’s Elrexfio (elranatamab) has been accepted by the Scottish Medicines Consortium (SMC) for use as a monotherapy in adults with relapsed and refractory multiple myeloma. The BCMA-directed ...

The Medscape team will be returning to the Alliance Industry Summit in Philadelphia this year, bringing with them Best in Class Outcomes and support for the event. As part of their dedication to and ...

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of planning and execution—strategy, integrated solution ...

Gilead Sciences and artificial intelligence (AI)-focused Genesis Therapeutics have entered into a collaboration aimed at developing small molecule therapies across multiple targets. The partners will ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo’s investigational antibody-drug conjugate (ADC) ifinatamab deruxtecan has demonstrated promising results in a mid-stage lung ...

Sanofi and Regeneron’s Dupixent (dupilumab) has demonstrated significant improvements in itch and hives for patients with chronic spontaneous urticaria (CSU), according to late-stage results shared by ...

GSK’s “ultra-long-acting” biologic depemokimab has demonstrated a significant reduction in severe asthma exacerbations over ...